Afficher la notice abrégée

Early use of hybrid closed-loop following total pancreaticoduodenectomy.

dc.rights.licenseopenen_US
dc.contributor.authorLARROUMET, Alice
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorMARICHEZ, Arthur
dc.contributor.authorCAMOIN, Marion
dc.contributor.authorBAILLET-BLANCO, Laurence
dc.contributor.authorADAM, Jean-Philippe
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorLAURENT, Christophe
dc.contributor.authorRIGALLEAU, Vincent
IDREF: 069788146
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorMOHAMMEDI, Kamel
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorCHICHE, Laurence
dc.date.accessioned2025-03-04T13:29:38Z
dc.date.available2025-03-04T13:29:38Z
dc.date.issued2025-03-01
dc.identifier.issn1878-1780en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205346
dc.description.abstractEnDiabetes secondary to total pancreaticoduodenectomy (TP) is challenging to manage due to high glycemic variability and risk of hypoglycemia, in a frail population. We report the case of four patients with no prior diabetes who underwent TP. Three of four patients needed artificial nutritional support. Hybrid closed-loop (HCL) insulin therapy was initiated within 12 weeks of surgery. After 90 days of HCL treatment, continuous glucose measurement showed a 70.4 ± 11.8 % time in range (versus 43 ± 6.5 % before HCL); 0.2 ± 0.2 % time below range (versus 0.6 ± 0.5 % before HCL); 23.8 ± 9.1 % time above range 180-250 mg/dl (versus 22.9 ± 6.1 % before HCL); 4.2 ± 2.5 % time above range > 250 mg/dl (versus 33.8 ± 3.9 % before HCL). The glucose management indicator improved from 8.5 ± 0.6 % to 6.9 ± 0.6 %. There was no severe hypoglycemia or need for unplanned medical attention. Early post-operative use of HCL allowed our patients to achieve safely optimal glycemic control after TP.
dc.language.isoENen_US
dc.subject.enHumans
dc.subject.enPancreaticoduodenectomy
dc.subject.enMale
dc.subject.enFemale
dc.subject.enAged
dc.subject.enMiddle Aged
dc.subject.enInsulin
dc.subject.enBlood Glucose
dc.subject.enHypoglycemic Agents
dc.subject.enInsulin Infusion Systems
dc.subject.enGlycemic Control
dc.title.enEarly use of hybrid closed-loop following total pancreaticoduodenectomy.
dc.title.alternativeDiabetes Metaben_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.diabet.2025.101619en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed39904482en_US
bordeaux.journalDiabetes & Metabolismen_US
bordeaux.page101619en_US
bordeaux.volume51en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04976114
hal.version1
hal.date.transferred2025-03-04T13:29:40Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes%20&%20Metabolism&rft.date=2025-03-01&rft.volume=51&rft.issue=2&rft.spage=101619&rft.epage=101619&rft.eissn=1878-1780&rft.issn=1878-1780&rft.au=LARROUMET,%20Alice&MARICHEZ,%20Arthur&CAMOIN,%20Marion&BAILLET-BLANCO,%20Laurence&ADAM,%20Jean-Philippe&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée